Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke

Journal of Neuroimmunology

Volumn 227, Issue 1-2, 2010, Pages 93-100

  Shin, Jin A ^a   Lee, Hyunah ^a   Lim, Yoo Kyoung ^a   Koh, Yaekyu ^a   Choi, Ji Ha ^a   Park, Eun Mi ^a,b  

^a Ewha Womans University School of Medicine   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

Acute ischemic stroke; Microglial activation; Pro inflammatory cytokines; Reactive oxygen species; Resveratrol; Sex difference

Indexed keywords

INTERLEUKIN 1BETA; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; GENE EXPRESSION; IMMUNOFLUORESCENCE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN INFARCTION; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; IMMUNOLOGY; METABOLISM; STROKE;

ACUTE DISEASE; ANIMALS; BRAIN INFARCTION; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; STILBENES; STROKE;

EID: 77956647573     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.06.017     Document Type: Article

References (53)

1. Basly J.P., Marre-Fournier F., Le Bail J.C., Habrioux G., Chulia A.J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 2000, 66:769-777.
2. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
3. Bi X.L., Yang J.Y., Dong Y.X., Wang J.M., Cui Y.H., Ikeshima T., Zhao Y.Q., Wu C.F. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int. Immunopharmacol. 2005, 5:185-193.
4. Bindokas V.P., Jordan J., Lee C.C., Miller R.J. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J. Neurosci. 1996, 16:1324-1336.
5. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141:3657-3667.
6. Bureau G., Longpre F., Martinoli M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 2008, 86:403-410.
7. Candelario-Jalil E., de Oliveira A.C., Graf S., Bhatia H.S., Hull M., Munoz E., Fiebich B.L. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J. Neuroinflammation 2007, 4:25.
8. Carter W.O., Narayanan P.K., Robinson J.P. Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J. Leukoc. Biol. 1994, 55:253-258.
9. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., Mucke L., Gan L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 2005, 280:40364-40374.
10. Cho S., Park E.M., Zhou P., Frys K., Ross M.E., Iadecola C. Obligatory role of inducible nitric oxide synthase in ischemic preconditioning. J. Cereb. Blood Flow Metab. 2005, 25:493-501.
11. Colton C.A., Gilbert D.L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 1987, 223:284-288.
12. de la Lastra C.A., Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 2005, 49:405-430.
13. Dong W., Li N., Gao D., Zhen H., Zhang X., Li F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J. Vasc. Surg. 2008, 48:709-714.
14. dos Santos A.Q., Nardin P., Funchal C., de Almeida L.M., Jacques-Silva M.C., Wofchuk S.T., Goncalves C.A., Gottfried C. Resveratrol increases glutamate uptake and glutamine synthetase activity in C6 glioma cells. Arch. Biochem. Biophys. 2006, 453:161-167.
15. Evenson K.R., Rosamond W.D., Morris D.L. Prehospital and in-hospital delays in acute stroke care. Neuroepidemiology 2001, 20:65-76.
16. Fisher M., Feuerstein G., Howells D.W., Hurn P.D., Kent T.A., Savitz S.I., Lo E.H. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250.
17. Gao D., Zhang X., Jiang X., Peng Y., Huang W., Cheng G., Song L. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci. 2006, 78:2564-2570.
18. Gehm B.D., McAndrews J.M., Chien P.Y., Jameson J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14138-14143.
19. Ginsberg M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008, 55:363-389.
20. Giulian D., Baker T.J., Shih L.C., Lachman L.B. Interleukin 1 of the central nervous system is produced by ameboid microglia. J. Exp. Med. 1986, 164:594-604.
21. Hailer N.P. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog. Neurobiol. 2008, 84:211-233.
22. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
23. Huang S.S., Tsai M.C., Chih C.L., Hung L.M., Tsai S.K. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci. 2001, 69:1057-1065.
24. Hurn P.D., Macrae I.M. Estrogen as a neuroprotectant in stroke. J. Cereb. Blood Flow Metab. 2000, 20:631-652.
25. Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 2003, 352:203-206.
26. Ito D., Tanaka K., Suzuki S., Dembo T., Fukuuchi Y. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 2001, 32:1208-1215.
27. Juan M.E., Maijo M., Planas J.M. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 2010, 51:391-398.
28. Karaoglan A., Akdemir O., Barut S., Kokturk S., Uzun H., Tasyurekli M., Colak A. The effects of resveratrol on vasospasm after experimental subarachnoidal hemorrhage in rats. Surg. Neurol. 2008, 70:337-343.
29. Katzan I.L., Furlan A.J., Lloyd L.E., Frank J.I., Harper D.L., Hinchey J.A., Hammel J.P., Qu A., Sila C.A. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. Jama 2000, 283:1151-1158.
30. Kondo T., Reaume A.G., Huang T.T., Carlson E., Murakami K., Chen S.F., Hoffman E.K., Scott R.W., Epstein C.J., Chan P.H. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J. Neurosci. 1997, 17:4180-4189.
31. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?. Eur. J. Endocrinol. 1998, 138:619-620.
32. Lin T.N., He Y.Y., Wu G., Khan M., Hsu C.Y. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993, 24:117-121.
33. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
34. Lu K.T., Chiou R.Y., Chen L.G., Chen M.H., Tseng W.T., Hsieh H.T., Yang Y.L. Neuroprotective effects of resveratrol on cerebral ischemia-induced neuron loss mediated by free radical scavenging and cerebral blood flow elevation. J. Agric. Food Chem. 2006, 54:3126-3131.
35. McCullough L.D., Hurn P.D. Estrogen and ischemic neuroprotection: an integrated view. Trends Endocrinol. Metab. 2003, 14:228-235.
36. Miller M.A. Gender-based differences in the toxicity of pharmaceuticals-the Food and Drug Administration's perspective. Int. J. Toxicol. 2001, 20:149-152.
37. Nicolini G., Rigolio R., Miloso M., Bertelli A.A., Tredici G. Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci. Lett. 2001, 302:41-44.
38. Okawara M., Katsuki H., Kurimoto E., Shibata H., Kume T., Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol. 2007, 73:550-560.
39. Park E.M., Cho S., Frys K., Racchumi G., Zhou P., Anrather J., Iadecola C. Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury. Stroke 2004, 35:2896-2901.
40. Park E.M., Cho S., Frys K., Glickstein S., Zhou P., Anrather J., Ross M., Iadecola C. Inducible nitric oxide synthase contributes to gender differences in ischemic brain injury. J. Cereb. Blood Flow Metab. 2006, 26:392-401.
41. Reed S.D., Cramer S.C., Blough D.K., Meyer K., Jarvik J.G. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001, 32:1832-1840.
42. Schwartz J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 2003, 42:107-121.
43. Shin J.A., Park E.M., Choi J.S., Seo S.M., Kang J.L., Lee K.E., Cho S. Ischemic preconditioning-induced neuroprotection is associated with differential expression of IL-1beta and IL-1 receptor antagonist in the ischemic cortex. J. Neuroimmunol. 2009, 217:14-19.
44. Shin J.A., Lee E.J., Seo S.M., Kim H.S., Kang J.L., Park E.M. Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse. Neuroscience 2010, 165:445-454.
45. Sinha K., Chaudhary G., Gupta Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 2002, 71:655-665.
46. Sun A.Y., Simonyi A., Sun G.Y. The "French Paradox" and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med. 2002, 32:314-318.
47. Tsai S.K., Hung L.M., Fu Y.T., Cheng H., Nien M.W., Liu H.Y., Zhang F.B., Huang S.S. Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J. Vasc. Surg. 2007, 46:346-353.
48. Wang Q., Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., Sun G.Y., Sun A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 2002, 958:439-447.
49. Wang Q., Tang X.N., Yenari M.A. The inflammatory response in stroke. J. Neuroimmunol. 2007, 184:53-68.
50. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13496-13500.
51. Zamin L.L., Dillenburg-Pilla P., Argenta-Comiran R., Horn A.P., Simao F., Nassif M., Gerhardt D., Frozza R.L., Salbego C. Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of PI3-K pathway. Neurobiol. Dis. 2006, 24:170-182.
52. Zhang N., Komine-Kobayashi M., Tanaka R., Liu M., Mizuno Y., Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005, 36:2220-2225.
53. Zhang H., Schools G.P., Lei T., Wang W., Kimelberg H.K., Zhou M. Resveratrol attenuates early pyramidal neuron excitability impairment and death in acute rat hippocampal slices caused by oxygen-glucose deprivation. Exp. Neurol. 2008, 212:44-52.